…associated with medication overuse headache or rebound headache in clinical trials, although overuse of any type of medicinal products for headache can make them worse. VYDURA® is commercialised as Nurtec®…
Content Section:
News Posts
Analysis of consistency in migraine days over the course of a dosing regimen for AJOVY® (fremanezumab-vfrm) Injection published in Headache – Analysis assessed migraine days at the beginning and end…
Content Section:
News Posts
… Discussion may also centre around postconcussion syndrome, acute post-traumatic headache, delayed-onset persistent headache attributable to mild traumatic brain injury (International Classification of Headache Disorders ICD-3) and post-traumatic stress disorder…
Content Section:
Articles
…essentials:Headache Pract Neurol 2008;8:335-43. doi:10.1136/jnnp.2008.159095 Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache. Neurology 2008:70:1555-63. Temporal arteritis. J R Coll Physicians Edinb 2012:42:341-9…
Content Section:
Conference Reports
…set the burglar alarm at their house or read the newspaper. The episode was associated with a mild, throbbing, bi-temporal headache that reached maximum intensity over a couple of minutes….
Content Section:
Case Reports
…Public Awareness Day was organised around the theme Diagnosing, Treating and Managing Headache and Sleep Disorders at the Neurology Lecture Hall in the Alte Nervenklinik at the Charité Campus. The…
Content Section:
Conference Reports
…to reduce the number of days that patients with medication overuse suffer from migraine headaches, as well as the quantity of medication for the treatment of acute migraine attacks they…
Content Section:
News Posts
…sufferer feeling helpless,” comments Dr Mark Weatherall, Chair of the British Association for the Study of Headache. “Fremanezumab is well tolerated, effective and particularly useful for complex migraine patients, where…
Content Section:
News Posts
…monthly-migraine-days and monthly-headache-days with both quarterly and monthly fremanezumab compared with placebo. Differences were also seen in patient-reported depressive symptoms using a PHQ-9 questionnaire – a brief self-reporting instrument incorporating…
Content Section:
News Posts